

# One Step Fentanyl Drug of Abuse Test

(Strip, Dipcard, Cassette)

For Harm Reduction Use or Forensic Use Only

## INTENDED USE

The One Step Fentanyl Drug of Abuse Test is a lateral flow chromatographic immunoassay for the qualitative detection of Fentanyl in substances for harm reduction use only or urine for forensic use only at the following cut-off concentration:

TEST	CALIBRATOR	CUT-OFF
Fentanyl (FEN)	Fentanyl	10 ng/mL
Fentanyl (FEN20)	Fentanyl	20 ng/mL

This assay provides only a preliminary qualitative test result. Use a more specific alternate quantitative analytical method to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) or Liquid chromatography/mass spectrometry (LC/MS) is the preferred confirmatory method.<sup>1</sup> Apply clinical and professional judgment to Fentanyl test result, particularly when a preliminary positive result is obtained.

## SUMMARY AND EXPLANATION OF THE TEST

The One Step Fentanyl Drug of Abuse Test is a competitive immunoassay utilizing highly specific reactions between antibodies and antigens for the detection of Fentanyl in substances or urine without the use of an instrument.

### FENTANYL (FEN)

Fentanyl is a potent, synthetic opioid analgesic with a rapid onset and short duration of action.<sup>7</sup> It is a strong agonist at the  $\mu$ -opioid receptors. Historically, it has been used to treat breakthrough pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic in combination with a benzodiazepine. Fentanyl is approximately 80 to 100 times more potent than morphine and roughly 15 to 20 times more potent than heroin.<sup>8,9</sup> Fentanyl and its derivatives are used recreationally. Deaths have resulted from both recreational and improper medical use.<sup>10</sup>

The FEN assay contained within the One Step Fentanyl Drug of Abuse Test yields a positive result when the concentration of Fentanyl in substances or urine exceeds 10 ng/mL.

### FENTANYL (FEN20)

The FEN assay contained within the One Step Fentanyl Drug of Abuse Test yields a positive result when the concentration of Fentanyl in substances or urine exceeds 20 ng/mL.

## PRINCIPLE

The One Step Fentanyl Drug of Abuse Test is an immunoassay based on the principle of competitive binding. A drug which may be present in the substances or urine specimen competes against its respective drug conjugate for binding sites on its specific antibody. During testing, a substances or urine specimen migrates upward by capillary action. A drug, if present in the substances or urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region. A drug-positive substances or urine specimen will not generate a colored line in the specific test line region of the strip because of drug competition, whereas a drug-negative substances or urine specimen will generate a line in the test line region because of the absence of drug competition. To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

## REAGENTS

The test contains a membrane strip coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to Fentanyl.

## PRECAUTIONS

- For Harm Reduction Use or Forensic Use Only
- Do not use after the expiration date.
- The test device should remain in the sealed pouch until use.
- The test is for single use.
- While urine is not classified by OSHA or the CDC as a biological hazard unless visibly contaminated with blood,<sup>14</sup> the use of gloves is recommended to avoid unnecessary contact with the specimen.
- The used test device and urine specimen should be discarded according to federal, state and local regulations.

## STORAGE AND STABILITY

Store as packaged in the sealed pouch at 4-30°C (39-86° F). The test is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

## SPECIMEN COLLECTION AND PREPARATION

### Substances or Urine Assay

If the substance you are testing is in liquid form, or if you are testing substances or urine, proceed to the respective Step 1 (see directions below) which corresponds to your device. If the substance you are testing is in powder form, place substance in a container and add water to the substance and mix well. Proceed to the respective Step 1 (see directions below) which corresponds to your device. If the substance you are testing is in pill format, crush or scrape some of the pill into a container. Add water to the substance and mix well. Proceed to the respective Step 1 (see directions below) which corresponds to your device.

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be allowed to settle to obtain a clear specimen for testing.

## MATERIALS

### Materials Provided

- Test device
- Desiccants
- Package insert
- Disposable specimen droppers (for test cassette use only)

### Materials Required But Not Provided


- Specimen collection container
- Timer
- Disposable gloves

## DIRECTIONS FOR USE

Allow the test device substance, or urine specimen to come to room temperature [15-30°C (59-86°F)] prior to testing.

### [For Strip]


- Remove strip from its foil pouch or the desiccated container (bring the container to the room temperature before opening to avoid condensation of moisture in container). Label the strip with patient or control identifications.
- Insert the test strip into the substance or urine sample for 15 seconds with the arrow end pointing towards the substance or urine. Do not let the substance or urine sample touch the MAX (maximum) line on the test strip, this could cause an inconclusive result. After 15 seconds, place the test strip on a flat surface.
- Read result at 3 minutes. **DO NOT READ RESULT AFTER 5 MINUTES. (Fig. 1)**



(Fig. 1)

### [For Cassette]


- Remove the test device from its foil pouch (bring the container to room temperature before opening to avoid condensation of moisture in container). Label the device with patient or control identifications.
- Using the specimen dropper, withdraw the substances or urine sample from the specimen container and slowly dispense 3 drops (approximately 120  $\mu$ L) into the circular sample well, being careful not to overfill the absorbent pad.
- Read result at 3 minutes. **DO NOT READ RESULT AFTER 5 MINUTES. (Fig. 2)**



(Fig. 2)

### [For Dipcard]

- Remove the test device from its foil pouch.
- Remove the cap from the test device. Label the device with patient or control identifications.
- Immerse the absorbent tip into the substances or urine sample for 15 seconds. Substances or urine sample should not touch the plastic device.
- Replace the cap over the absorbent tip and lay the device flat on a non-absorptive clean surface.
- Read result at 3 minutes. **DO NOT READ RESULT AFTER 5 MINUTES. (Fig. 3)**



(Fig. 3)

## INTERPRETATION OF RESULTS

**NEGATIVE:** Two lines appear. \*One color line should be in the control region (C) and another apparent color line adjacent should be in the test region (T). This negative result indicates that the drug concentration is below the detectable level.

\*NOTE: The shade of color in the test line region (T) will vary, but it should be considered negative when there is even a faint distinguishable color line.

**POSITIVE:** One color line appears in the control region (C). No line appears in the test region (T). This positive result indicates that the drug concentration is above the detectable level.

**INVALID:** Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test device. If the problem persists, discontinue using the lot immediately and contact your supplier.

## QUALITY CONTROL

A procedural control is included in the test. A color line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

## LIMITATIONS

- The One Step Fentanyl Drug of Abuse Test provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) or Liquid chromatography-mass spectrometry (LC/MS) is the preferred confirmatory method.
- There is a possibility that technical or procedural errors, as well as other interfering substances in the substances or urine specimen may cause erroneous results.
- A positive result does not indicate intoxication of the donor, the concentration of drug in the substances or urine, or the route of drug administration.
- A negative result may not necessarily indicate drug-free substances or urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- Test does not distinguish between drugs of abuse and certain medications.
- A positive test result may be obtained from certain foods or food supplements.
- The test device is NOT intended to determine the purity, composition, or if the substance being examined is safe to use.
- A positive or negative test result is NOT an indication that the substance being examined is safe to use. Many factors come into play when examining the samples, including but not limited to mixture of multiple substances, solubility, and pH of the sample.
- The use, supply, or production of illegal drugs or controlled substances is not encouraged in any way. The device is intended for harm reduction purposes. Follow the advice of your local harm reduction or public health agency.

## PERFORMANCE CHARACTERISTICS

### Reproducibility For Fen

Reproducibility studies were carried out using commercially available stock solutions of the drug analytes listed. The results are listed in the following table.

FENTANYL CONCENTRATION (ng/mL)	TOTAL NUMBER OF DETERMINATIONS	RESULT	PRECISION
No Drug Present	60	60 negative	>99%
5	60	60 negative	>99%
15	60	60 positive	>99%

### Reproducibility For Fen20

Reproducibility studies were carried out using commercially available stock solutions of the drug analytes listed. The results are listed in the following table.

FENTANYL CONCENTRATION (ng/mL)	TOTAL NUMBER OF DETERMINATIONS	RESULT	PRECISION
No Drug Present	60	60 negative	>99%
10	60	60 negative	>99%
30	60	60 positive	>99%

### Analytical Sensitivity For Fen

A drug-free substances or urine pool was spiked with drug at concentrations listed. The results are summarized below.

DRUG CONCENTRATION CUT-OFF RANGE	n	FEN	
		-	+
0% Cut-Off	30	30	0
-50% Cut-Off	30	30	0
-25% Cut-Off	30	30	0
Cut-Off	30	3	27
+25% Cut-Off	30	0	30
+50% Cut-Off	30	0	30

### Analytical Sensitivity For Fen20

A drug-free substances or urine pool was spiked with drug at concentrations listed. The results are summarized below.

DRUG CONCENTRATION CUT-OFF RANGE	n	FEN	
		-	+
0% Cut-Off	30	30	0
-50% Cut-Off	30	30	0
-25% Cut-Off	30	30	0
Cut-Off	30	3	27
+25% Cut-Off	30	0	30
+50% Cut-Off	30	0	30

### Analytical Specificity For Fen

The following table lists the concentration of compounds (ng/mL) that were detected positive in substances or urine by the One Step Fentanyl Drug of Abuse Test at a read time of 5 minutes.

Compound Name	Positive result at	Cross-reactivity (%)
Acetyl- $\alpha$ -methyl fentanyl	50ng/ml	20%
Acryl fentanyl	40ng/ml	25%
$\alpha$ -methyl fentanyl	10ng/ml	100%
Benzyl fentanyl	25ng/ml	40%
$\beta$ -hydroxythio fentanyl	10ng/ml	100%
Cyclopropyl fentanyl	10ng/ml	100%
4-Fluoroisobutyl fentanyl	1000ng/ml	0.1%
Methoxyacetyl fentanyl	125ng/ml	8%
4-methoxybutyl fentanyl (para)	400ng/ml	0.25%
4'-methyl acetyl fentanyl	250ng/ml	4%
3'-methyl Fentanyl	10ng/ml	100%
N-methyl norfentanyl	15ng/ml	66.7%
o-Fluorofentanyl	25ng/ml	40%
p-Fluorobutyl fentanyl	20ng/ml	50%
Tetrahydrofuran fentanyl	500ng/ml	0.2%
2-Thiofuranyl fentanyl	500ng/ml	2%
4-Piperidone	2500ng/ml	0.04%
2',4'-dimethoxy Fentanyl	25ng/ml	40%
3',4'-dimethoxy Fentanyl	5ng/ml	200%
meta-fluoro Acrylfentanyl	25ng/ml	40%
para-chloro Furanyl fentanyl 3-furancarboxamide	50ng/ml	20%
Thiophene fentanyl 3-thiophenecarboxamide	250ng/ml	4%
3'-Fluorofentanyl	12.5ng/ml	80%
ortho-fluoro Valeryl fentanyl	500ng/ml	0.2%
4-methyl Fentanyl	50ng/ml	20%
Cyclopropaneacetyl fentanyl	25ng/ml	40%
para-Chloroacetyl fentanyl	50ng/ml	20%
para-hydroxy Butyl fentanyl	15ng/ml	66.7%
2'-Fluoro ortho-Fluorofentanyl	100ng/ml	10%
meta-methoxy Furanyl fentanyl	250ng/ml	4%
3'-fluoro ortho-Fluorofentanyl	50ng/ml	20%
2',3'-dimethoxy Fentanyl	10ng/ml	100%
2',6'-dimethoxy Fentanyl	25ng/ml	40%
3',5'-dimethoxy Fentanyl	2.5ng/ml	400%
Acetyl norfentanyl	100ng/ml	1%

### Analytical Specificity For Fen20

The following table lists the concentration of compounds (ng/mL) that were detected positive in substances or urine by the One Step Fentanyl Drug of Abuse Test at a read time of 5 minutes.

Compound Name	Positive result at	Cross-reactivity (%)
Acetyl- $\alpha$ -methyl fentanyl	200ng/ml	10%
Acryl fentanyl	125ng/ml	16%
$\alpha$ -methyl fentanyl	20ng/ml	100%
Benzyl fentanyl	50ng/ml	40%
$\beta$ -hydroxythio fentanyl	25ng/ml	80%
Cyclopropyl fentanyl	25ng/ml	80%
4-Fluoroisobutyl Fentanyl	40,000ng/ml	0.05%
Methoxyacetyl fentanyl	500ng/ml	4%
4-methoxybutyl fentanyl (para)	7500ng/ml	0.27%
4'-methyl acetyl fentanyl	1000ng/ml	2%
3'-methyl Fentanyl	25ng/ml	80%
N-methyl norfentanyl	25ng/ml	80%
o-Fluorofentanyl	75ng/ml	26.7%
p-Fluorobutyl fentanyl	50ng/ml	40%
Tetrahydrofuran fentanyl	25,000ng/ml	0.08%
2-Thiofuranyl fentanyl	2500ng/ml	8%
2',4'-dimethoxy Fentanyl	50ng/ml	40%
3',4'-dimethoxy Fentanyl	12.5ng/ml	160%
meta-fluoro Acrylfentanyl	100ng/ml	20%
para-chloro Furanyl fentanyl 3-furancarboxamide	125ng/ml	16%
Thiophene fentanyl 3-thiophenecarboxamide	500ng/ml	4%
3'-Fluorofentanyl	25ng/ml	80%
ortho-fluoro Valeryl fentanyl	6000ng/ml	0.33%
4-methyl Fentanyl	250ng/ml	40%
Cyclopropaneacetyl fentanyl	100ng/ml	20%
para-Chloroacetyl fentanyl	250ng/ml	8%
para-hydroxy Butyl fentanyl	25ng/ml	80%
2'-Fluoro ortho-Fluorofentanyl	250ng/ml	8%
meta-methoxy Furanyl fentanyl	1000ng/ml	2%
3'-fluoro ortho-Fluorofentanyl	150ng/ml	13.3%
2',3'-dimethoxy Fentanyl	20ng/ml	100%
2',6'-dimethoxy Fentanyl	75ng/ml	26.7%
3',5'-dimethoxy Fentanyl	10ng/ml	200%
Acetyl norfentanyl	2500ng/ml	0.8%

### EFFECT OF URINARY SPECIFIC GRAVITY

Urine samples of normal, high, and low specific gravity ranges from 1.000 - 1.025 were spiked with drug at 50% below and 50% above cut-off levels respectively and tested using One Step Fentanyl Drug of Abuse Test. The results demonstrate that varying ranges of specimen specific gravity do not interfere with the performance of the test.

### EFFECT OF URINARY PH

The pH of an aliquoted negative urine pool was adjusted to pH ranges of 4.0, 4.5, 5.0, 6.0 and 9.0, and spiked with drug at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the One Step Fentanyl Drug of Abuse Test. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

### INTERFERENCE

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free substances or urine, or drug positive substances or urine containing Fentanyl. Parent Compound Only.

The following compound shows no cross-reactivity when tested with the One Step Fentanyl Drug of Abuse Test at concentrations of 10  $\mu$ g/ml.

### Carfentanil

The following compounds show no cross-reactivity when tested with the One Step Fentanyl Drug of Abuse Test at concentrations of 100  $\mu$ g/ml.

Acebutolol  
 Acetopromazine-d6  
 Acetyl-L-cysteine  
 Acetylsalicylic Acid (Aspirin)  
 Acetaminophen  
 O6-Acetylmorphine Acetazolamide  
 N-Acetylprocainamide  
 Acetone  
 Acetophenetidin  
 Cinchonidine  
 Cinoxacin  
 Clcospirin  
 Citric acid  
 Clenbuterol Hydrochloride  
 Clindamycin  
 Clodetasone Butyrate  
 Clomipramine  
 Clorazepate Dipotassium  
 Clonazepam  
 Clobazam  
 Cloxacillin  
 Cholesterol  
 (-)-Cotinine  
 Cocaethylene  
 Cocaine Hydrochloride  
 Codeine  
 Creatinine  
 Chlorothiazide  
 Camphor  
 Clonidine hydrochloride  
 Canrenoic acid  
 Captopril  
 Clozapine  
 Chloramphenicol  
 Aspartame  
 L-Ascorbic Acid  
 L-Aspartic Acid  
 D-Aspartic Acid  
 DL-Aspartic Acid  
 Atenolol  
 Atropine  
 Baclofen  
 Benzphetamine  
 Barbituric Acid  
 Berberine  
 Benzocaine  
 Benzyl alcohol  
 Benzoylcocgonine  
**Benzoyl fentanyl (Phenyl fentanyl)**  
 Bendroflumethiazide  
 Beclomethasone  
 Benzalkonium bromide  
 Benzthiazide  
 Benzylamine Hydrochloride  
 Bisacodyl  
**Brorphine**  
 Bromazepam  
 Bupivacaine  
 Buprenorphine  
 Buprenorphine-3P-D-glucuronide  
 Bupropion hydrochloride  
 Buspirone  
 Butacaine  
 Butabarbital  
 Butyrophenone  
 Butethal  
 Caffeine  
 Carbamazepine  
 Carisoprodol  
 Cefaclor  
 Ceftriaxone  
 Cefotaxime  
 Cefoxitin  
 Cefuroxime Axetil (Zinnat)  
 Cefadroxil  
 Cephradine  
 Chloroquine  
 Chlorpheniramine  
 Chlorpromazine  
 Chlorpropamide  
 Chlorprothixene  
 Chlorthalidone  
 Chlorzoxazone  
 Chloral Hydrate  
 Cimetidine  
 Cinchonidine  
 Cinoxacin  
 Cicospirin  
 Citric acid  
 Clenbuterol Hydrochloride  
 Clindamycin  
 Clodetasone Butyrate  
 Clomipramine  
 Clorazepate Dipotassium  
 Clonazepam  
 Clobazam  
 Cloxacillin  
 Cholesterol  
 (-)-Cotinine  
 Cocaethylene  
 Cocaine Hydrochloride  
 Codeine  
 Creatinine  
 Chlorothiazide  
 Camphor  
 Clonidine hydrochloride  
 Canrenoic acid  
 Captopril  
 Clozapine  
 Chloramphenicol  
 Cortisone  
 a-Chymotrypsin  
 Cetirizine Hydrochloride Tablets  
 Cyclobenzaprine Hydrochloride  
 L-Cystine  
 Cyproheptadine Hydrochloride  
 Cyclopentobarbital  
 Chlorothiazide  
 Camphor  
 Clonidine hydrochloride  
 Canrenoic acid  
 Captopril  
 Clozapine  
 Chloramphenicol  
 Cortisone  
 a-Chymotrypsin  
 Cetirizine Hydrochloride Tablets  
 Dextromethorphan  
 Dextrorphan hydrobromide  
 Dexamethasone  
 Deoxyepinephrine  
 Deferoxamine Mesylate  
**Despropionyl ortho-Fluorofentanyl**  
 Diazoxide  
 Dieldrin  
 Desipramine  
 Desoximetasone  
 Dimethyl Isosorbide  
 Diazepam  
 Diflorasone Diacetate  
 Diflunisal  
 Dipyrindamole  
 Dipyrone  
 5,5-Diphenylhydantoin  
 D,L-3,4-Dihydroxymandelic acid  
 Dihydralazine  
 Disopyramide  
 Dopamine  
 Dobutamine  
 Doxepin  
 Doxycycline Hytclate Doxylamine  
 Droperidol  
 Ecgonine methylester

Ephedrine-(+/-)  
 Erythromycin  
 Eserine  
 Estazolam  
 Estradiol, 17B-  
 Estriol  
 Estrone  
 Estrone-3-sulfate  
 Etoposide  
 Ethacrynic Acid  
 Ethambutol  
 Ethyl-p-aminobenzoate  
 Ethylenediamine Tetraacetic  
 Etodolac  
**Etonitazene**  
 Ethyl Morphine  
 R(-)-Epinephrine  
 Emetine dihydro-chloride hydrate  
 Ethyl acetate  
 Famotidine  
 Fenfluramine  
 Ferrous Sulfate  
 Fenoprofen  
 Flufenamic Acid  
 Flunitrazepam  
 Flunisolide  
 Fluphenazine dihydrochloride  
 Flurandrenolide  
 Flurazepam  
 Furosemide  
 Gentamicin Sulfate  
 Glutathione reduced  
 Glybenclamide  
 Griseofulvin  
 Halcinonide  
 Hemoglobin  
 Heroin  
 Hexachlorophene  
 Hypnoval (Cyclobarbital)  
 Hippuric Acid  
 Histamine  
 Hydralazine  
 (1 R,9S)-(-)-p-Hydrastine  
 Hydroflumethiazide  
 Hydromorphone  
 Hydrocodone  
 Hydroxocobalamin hydrochloride  
 a -Hydroxyhippuric acid  
 Hydroxyzine dihydrochloride  
 a-Hydroxyalprazolam  
 Hydroxyprogesterone  
 p-Hydroxymethamphetamine  
 Hydrocortisone  
 Hydrochlorothiazide  
 (+/-)-4-Hydroxyamphetamine HCL  
 Hydroxyurea  
 Haloperidol  
 Ibuprofen  
 Ifomifensine  
 Imipramine  
 Imidazole  
 Indapamide  
 Indomethacin  
 Ipratropium Bromide  
 Isonicotinic Acid  
 Isoxsuprine Isoproterenol-(+/-)  
**Isotonitazene**  
 Ketamine  
 Kynurenic Acid  
**Labetalol**  
 Lactose  
 Levorphanol  
 Lidocaine  
 Lithium Carbonate  
 Lorazepam glucuronide  
 Mannitol  
 Maprotiline  
 Mebendazole  
 Meclofenamic Acid  
 Medazepam  
 Mefenamic Acid  
 Melanin  
 Meperidine  
 Meprobamate  
 Merperidine  
 Metaraminol Methamphetamine

D-methamphetamine  
 o-Methoxyaniline HCL  
 Methoxyphenamine  
 Methylene Blue  
 Methylphenidate  
 Meticrane  
 Metoclopramide Hydrochloride  
 Metronidazole  
 4-Metylumbelliferyl B-D-glucuronide  
 hydrate  
 Mianserin  
 Milrinone  
 Minaprine  
 Morphine  
 Methyl salicylate  
 Methoxyamine hydrochloride  
 Metaproterenol hemisulfate salt  
 Nabumetone  
 Nadolol  
 Nafcillin  
 Nalbuphine  
 Nalorphine hydrochloride  
 Naphthol  
 Naproxen  
 Naphazoline hydrochloride  
 1-Naphthylacetic acid  
 1 Naloxone hydrochloride  
 Nalmefene  
 Neomycin Sulfate  
 Nialamide  
 Niacinamide  
 (+/-) Nicotine  
 Nimesulide  
 Nitrazepam  
 Nifedipine  
 Nicotinic Acid  
 Nitrofurantoin  
 Norchloridiazepoxide  
 Nordlomipramine  
 Nordiazepam  
 Nordoxepin  
 Norfloxacin  
 Norethindrone  
 Norpropoxyphene  
 Noscapine  
**Norcarfentanil**  
 Norfludiazepam  
 Nortriptyline Hydrochloride  
 Nyldrin  
 OxymorphoneOfloxacin  
 Oxazepam  
 Oxymetazoline  
 Oxyphenbutazone  
 Oxypurinol  
 Octopamine  
 Orphenadrine hydrochloride  
 Oxalic Acid  
 Pargyline  
 Picrotoxin  
 Potassium chloride  
 Propionylpromazine  
 Pancuronium Bromide  
 Papaverine  
 Paracetamol tablets  
 Paclitaxel  
 PCP Morpholine Analog  
 Pentobarbital  
 Pentylene tetrazole  
 Pentoxifylline  
 Perphenazine  
 Phenelzine  
 Penicillin  
 Phenacetin  
 Phencyclidine(PCP)  
 Phenformin  
 Pheniramine  
 Phenobarbital  
 Phenothiazine  
 Phenol  
 Phenolphthalien  
 Phentermine  
 P-phenylene  
 Phenylephrine-L  
 Phenylbutazone  
 Phenylethylamine

Phenylpropranolamine  
 Phenyltoloxamine  
 Pilocarpine  
 Pimozide  
**Piperidylthiambutene**  
 Pipecolic Acid  
 Piroxicam  
 Potassium Iodide  
 Prazepam  
 Prednisolone Acetate  
 Prilocaine  
 Primaquine diphosphate  
 Primidone  
 Proadifen  
 Probenecid  
 Procainamide hydrochloride  
 Procaine  
 Procyclidine  
 Promazine  
 Promethazine  
 Propoxyphene,d-  
 Propranolol  
 Protriptyline  
 Pseudoephedrine HCL  
 Pyridine-2-Aldoxime  
 Pyridoxine  
 Pylamine  
 2, 3-pyridine dicarboxylic acid  
 Quinine  
 Quinidine  
 Quinacrine  
 Sodium chloride  
 Ritodrine  
 Roxithromycin tablets  
 Ranitidine  
 Riboflavin  
 Salbutamol (Albuterol)  
 Salicylic Acid  
 Secobarbital  
 Serotonin  
 Sertaline  
 Sodium Cromoglicate  
 Sodium Formate  
 Stearic magnesium  
 Sulfamethazine  
 Sulfamethoxazole  
 Sulindac  
 Sulfathiazole  
 Sulfanilamide  
 Tamoxifen Citrate  
 Tannic Acid  
 Tenoxicam  
 Terfenadine

Terbutaline  
 Tetraethylthiuram disulfide  
 Tetracycline  
 Thebaine  
 Theobromine  
 Thiamine  
 Theophylline  
**Tianeptine**  
 Tobramycin  
 Tolazamide  
 Tolbutamide  
 Tolmetin  
 Triprolidine  
 Tramadol  
 Trazodone  
 2, 4, 6-trmethylbezamide  
 Tropic Acid  
 Tropine  
 D/L-Tyrosine  
 Trichloroacetic acid Trimipramine  
 Tryptamine  
 Trichlormethiazide  
 Trimethoprim  
 L-Thyroxine  
 Trifluoperazine  
 D, L-Tryptophan  
 Triazolam  
 Trans-2-phenylcyclo-propylamine  
 hydrochloride  
 Tyramine  
 Uric Acid  
 Urea  
 Vancomycin HCL  
 Venlafaxine hydrochloride  
 Verapamil  
 Vincamine  
 Vanillic acid diethylamine  
 Xylometazoline hydrochloride  
 Yohimbine  
 Zearalenone  
 Zomepirac  
 Zopiclone  
**4-Anilino-1-Boc-piperidine**  
**2-fluoro Viminol**  
**4-Anilino-1-benzylpiperidine**  
**AP-238**  
**2,3-Benzodioxole fentanyl**  
**N-Benzyl-4-piperidone**  
**4-Anilinopiperidine**  
**O-Desmethyl-cis-tramadol**  
**Despropionyl para-Fluoro fentanyl**  
**N-Phenethyl-4-piperidone(NPP)**  
**4-ANPP**  
**AP-237**  
**2-methyl AP-237**

#### BIBLIOGRAHY

1. Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, 264-8.
2. Hawks RL, CN Chaing. Substances or urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA). Research Monograph 73, 1986.
3. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
4. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA 1982; 487.
5. OSHA, The Bloodborne Pathogens Standard 29, Code of Federal Regulations 29 CFR 1910.1030.
6. CDC, Centers for Disease Control (CDC) Guidelines, Morbidity and Mortality Weekly Report, Volume 37, Number 24, 1988.
7. "WCPI Focus on Pain Series: The Faces of Fentanyl." Aspi.wisc.edu. Retrieved 2010-07-28.
8. "FENTANYL: Incapacitating Agent." CDC. Retrieved 2014-09-18.
9. Mutschler, Ernst; Schafer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche, Verlagsgesellschaft. p 286. ISBN 3-8047-1763-2.
10. Parry WH, Martorano F, Cotton EK (January 1976). "Management of life-threatening asthma with intravenous isoproterenol infusions." AM. J. Dis. Child. 130(1):39-42. doi:10.1001/archpedi.1976.02120020041006.

#### Manufactured By:

W.H.P.M., Inc.  
 5358 Irwindale Ave.  
 Irwindale, CA 91706

**www.whpm.com**  
**DGP36259**